[
  {
    "ts": null,
    "headline": "How tariffs impact pharma stocks",
    "summary": "Most companies are likely going to feel the impact of President Trump's tariffs. In the video above, BofA Securities senior pharma & biotech analyst Tim Anderson describes how tariffs will impact the pharmaceutical stocks he covers. He also explains why Eli Lilly (LLY) and Novo Nordisk (NVO) have a \"moat\" around them. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=9f87c2d1705f7ee4d319d25de3d5deaaa1f0307b972022e0e965222d2a73895c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745618959,
      "headline": "How tariffs impact pharma stocks",
      "id": 134104475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Most companies are likely going to feel the impact of President Trump's tariffs. In the video above, BofA Securities senior pharma & biotech analyst Tim Anderson describes how tariffs will impact the pharmaceutical stocks he covers. He also explains why Eli Lilly (LLY) and Novo Nordisk (NVO) have a \"moat\" around them. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=9f87c2d1705f7ee4d319d25de3d5deaaa1f0307b972022e0e965222d2a73895c"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly and Company (LLY) the Best Stock to Invest in for Long Term?",
    "summary": "We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to invest in for long term. The markets have had two monster years with the S&P 500 index […]",
    "url": "https://finnhub.io/api/news?id=18ae3ae43cc20083e70799eea7ceb1b489aaa40bcadb5853e45cbfabfcfecaa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745612873,
      "headline": "Is Eli Lilly and Company (LLY) the Best Stock to Invest in for Long Term?",
      "id": 134104476,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best stocks to invest in for long term. The markets have had two monster years with the S&P 500 index […]",
      "url": "https://finnhub.io/api/news?id=18ae3ae43cc20083e70799eea7ceb1b489aaa40bcadb5853e45cbfabfcfecaa5"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last",
    "summary": "Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.",
    "url": "https://finnhub.io/api/news?id=bda32673eb3a5288dc6f90336a57a69b0590967b5ace3c4738e445e3d2bb8f94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745606747,
      "headline": "Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last",
      "id": 134095037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.",
      "url": "https://finnhub.io/api/news?id=bda32673eb3a5288dc6f90336a57a69b0590967b5ace3c4738e445e3d2bb8f94"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Q1 Earnings Reinforce Positive Momentum",
    "summary": "AbbVie Inc.'s strong fundamentals, healthy dividends, and acceptable forward P/Es for the medium term make a case. Read more on ABBV earnings update.",
    "url": "https://finnhub.io/api/news?id=2d5e4b04a5ac5e407c51416adbb69373ff8835c4fe5385795837a15bc353363a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745596804,
      "headline": "AbbVie: Q1 Earnings Reinforce Positive Momentum",
      "id": 134095648,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc.'s strong fundamentals, healthy dividends, and acceptable forward P/Es for the medium term make a case. Read more on ABBV earnings update.",
      "url": "https://finnhub.io/api/news?id=2d5e4b04a5ac5e407c51416adbb69373ff8835c4fe5385795837a15bc353363a"
    }
  },
  {
    "ts": null,
    "headline": "This REIT’s 7% Dividend Yield Looks Solid",
    "summary": "This REIT’s 7% Dividend Yield Looks Solid",
    "url": "https://finnhub.io/api/news?id=7822cbf917159541138124f3d39a677d01d37d7dc39a64ae3b25f722fe0b7f2f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745589360,
      "headline": "This REIT’s 7% Dividend Yield Looks Solid",
      "id": 134146409,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "This REIT’s 7% Dividend Yield Looks Solid",
      "url": "https://finnhub.io/api/news?id=7822cbf917159541138124f3d39a677d01d37d7dc39a64ae3b25f722fe0b7f2f"
    }
  },
  {
    "ts": null,
    "headline": "Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom",
    "summary": "Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the stock. Despite broader market uncertainties, the company’s robust performance in the diabetes and obesity segments, particularly with GLP-1 drugs like Mounjaro and Zepbound, has bolstered analysts’ confidence. Overall, Wall Street expects an EPS (earnings per share) of $4.17, significantly higher than the $2.58 in Q1 2024. Notably, GLP-1 drugs help regulate b",
    "url": "https://finnhub.io/api/news?id=15a01766f5a4fc47b2ac46e46cb74cbd8961626ef07a6a492167f916f50670fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745586371,
      "headline": "Analysts Maintain Buy Ratings on Eli Lilly Stock (LLY) as Q1 Earnings Loom",
      "id": 134087580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the stock. Despite broader market uncertainties, the company’s robust performance in the diabetes and obesity segments, particularly with GLP-1 drugs like Mounjaro and Zepbound, has bolstered analysts’ confidence. Overall, Wall Street expects an EPS (earnings per share) of $4.17, significantly higher than the $2.58 in Q1 2024. Notably, GLP-1 drugs help regulate b",
      "url": "https://finnhub.io/api/news?id=15a01766f5a4fc47b2ac46e46cb74cbd8961626ef07a6a492167f916f50670fe"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates",
    "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 2.93% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=83aafd6c166ae14017f122ab18ac91e95ed2154ed6bc550c403a762ad79bc972",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745585702,
      "headline": "AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates",
      "id": 134087581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) delivered earnings and revenue surprises of 2.93% and 3.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=83aafd6c166ae14017f122ab18ac91e95ed2154ed6bc550c403a762ad79bc972"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook",
    "summary": "Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.",
    "url": "https://finnhub.io/api/news?id=5b803c5430b06056598660ea2c5c2bd35b072bc7c3e6ec33008a7c9828343b37",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745576360,
      "headline": "Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook",
      "id": 134081781,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1333603932/image_1333603932.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to expect from LLY's Q1 results.",
      "url": "https://finnhub.io/api/news?id=5b803c5430b06056598660ea2c5c2bd35b072bc7c3e6ec33008a7c9828343b37"
    }
  },
  {
    "ts": null,
    "headline": "The Best Stock to Buy With Less Than $60 in the Market Sell-Off",
    "summary": "One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for just $60 each, and as recently as last July, traded in the mid-140s.  Novo Nordisk is an outstanding business to own for this amount, even considering the recent issues it has faced.  There can also be disadvantages in overreliance on a single therapeutic area, and Novo Nordisk has long focused on endocrine-related disorders.",
    "url": "https://finnhub.io/api/news?id=18ffd96db10f6041ea3c8f087061477b739e5991f2a1a0780a13267b626fc2f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745575380,
      "headline": "The Best Stock to Buy With Less Than $60 in the Market Sell-Off",
      "id": 134087582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for just $60 each, and as recently as last July, traded in the mid-140s.  Novo Nordisk is an outstanding business to own for this amount, even considering the recent issues it has faced.  There can also be disadvantages in overreliance on a single therapeutic area, and Novo Nordisk has long focused on endocrine-related disorders.",
      "url": "https://finnhub.io/api/news?id=18ffd96db10f6041ea3c8f087061477b739e5991f2a1a0780a13267b626fc2f0"
    }
  },
  {
    "ts": null,
    "headline": "Trending tickers: Alphabet, Intel, Meta, Novo Nordisk and WPP",
    "summary": "The latest investor updates on stocks that are trending on Friday.",
    "url": "https://finnhub.io/api/news?id=3411bcd7105bf5bec76b17c0d3d372e0230a51ea1cd19af706245d68cbb46640",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745575089,
      "headline": "Trending tickers: Alphabet, Intel, Meta, Novo Nordisk and WPP",
      "id": 134087452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The latest investor updates on stocks that are trending on Friday.",
      "url": "https://finnhub.io/api/news?id=3411bcd7105bf5bec76b17c0d3d372e0230a51ea1cd19af706245d68cbb46640"
    }
  },
  {
    "ts": null,
    "headline": "Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?",
    "summary": "Biogenâs lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.",
    "url": "https://finnhub.io/api/news?id=ef3adb4bcd126997d1f1592527ecb2afc521115bd3cda32b4212595c2984fefe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745572551,
      "headline": "Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?",
      "id": 134077371,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165724853/image_2165724853.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Biogenâs lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.",
      "url": "https://finnhub.io/api/news?id=ef3adb4bcd126997d1f1592527ecb2afc521115bd3cda32b4212595c2984fefe"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca",
    "summary": "Earnings preview of key companies reporting next week and what to look out for.",
    "url": "https://finnhub.io/api/news?id=ca9edd4559b6c0357af687f6e1cde0db5177f361a0cc944c63fa7a6a219797cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745557219,
      "headline": "Stocks to watch next week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca",
      "id": 134067227,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings preview of key companies reporting next week and what to look out for.",
      "url": "https://finnhub.io/api/news?id=ca9edd4559b6c0357af687f6e1cde0db5177f361a0cc944c63fa7a6a219797cd"
    }
  },
  {
    "ts": null,
    "headline": "Buy Healthcare Stocks Despite RFK Jr., Tariffs, and UnitedHealth",
    "summary": "Buy Healthcare Stocks Despite RFK Jr., Tariffs, and UnitedHealth",
    "url": "https://finnhub.io/api/news?id=1b7627ffa34dbe65d9c7fca6c4584403ad6abb05f4febd9590389727c3f440ff",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745546400,
      "headline": "Buy Healthcare Stocks Despite RFK Jr., Tariffs, and UnitedHealth",
      "id": 134146410,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Buy Healthcare Stocks Despite RFK Jr., Tariffs, and UnitedHealth",
      "url": "https://finnhub.io/api/news?id=1b7627ffa34dbe65d9c7fca6c4584403ad6abb05f4febd9590389727c3f440ff"
    }
  }
]